Clinical Trial Update: MIC Cell Therapy for Individualized Immunosuppression in Living Donor Kidney Transplant Recipients [Phase 1]

View source ↗

Summary

Phase 1 study of MIC cell therapy to individualize immunosuppression in living donor kidney transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• MIC cell therapy

Snippet

Sponsor: Heidelberg University | Conditions: Kidney Failure, Chronic | Phase 1 | Status: COMPLETED